机构:
Cent South Univ, Hunan Canc Hosp, Dept Radiat Oncol, Changsha, Hunan, Peoples R China
Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Hunan, Peoples R China
Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USACent South Univ, Hunan Canc Hosp, Dept Radiat Oncol, Changsha, Hunan, Peoples R China
Lei, Guang
[1
,2
,3
]
Gan, Boyi
论文数: 0引用数: 0
h-index: 0
机构:
Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USACent South Univ, Hunan Canc Hosp, Dept Radiat Oncol, Changsha, Hunan, Peoples R China
Gan, Boyi
[3
]
机构:
[1] Cent South Univ, Hunan Canc Hosp, Dept Radiat Oncol, Changsha, Hunan, Peoples R China
[2] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Hunan, Peoples R China
[3] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA
来源:
JOURNAL OF EXPERIMENTAL MEDICINE
|
2022年
/
219卷
/
04期
关键词:
D O I:
10.1084/jem.20212166
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
How to specifically target oncogenic KRAS-driven cancers while sparing normal tissues remains an unmet need in cancer therapy. In this issue of JEM, Jiang et al. (2022. J. Exp. Med.) leveraged KRAS-induced iron addiction in cancer cells to design a clever drug delivery approach to enable selective inhibition of KRAS signaling in mutant KRAS tumors but not in normal tissues, offering a new strategy for treating this largely incurable disease.
机构:
Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
Harvard Med Sch, Boston, MA 02115 USABrigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA